Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
…, N Amirouchene-Angelozzi, S Marsoni, M D'Incalci… - Nature, 2017 - nature.com
Molecular alterations in genes involved in DNA mismatch repair (MMR) promote cancer
initiation and foster tumour progression 1 . Cancers deficient in MMR frequently show favourable …
initiation and foster tumour progression 1 . Cancers deficient in MMR frequently show favourable …
A review of trabectedin (ET-743): a unique mechanism of action
M D'Incalci, CM Galmarini - Molecular cancer therapeutics, 2010 - AACR
Trabectedin (ET-743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia
turbinata, with a chemical structure characterized by three fused tetrahydroisoquinoline …
turbinata, with a chemical structure characterized by three fused tetrahydroisoquinoline …
High-dose vitamin C enhances cancer immunotherapy
Vitamin C (VitC) is known to directly impair cancer cell growth in preclinical models, but
there is little clinical evidence on its antitumoral efficacy. In addition, whether and how VitC …
there is little clinical evidence on its antitumoral efficacy. In addition, whether and how VitC …
Unique features of trabectedin mechanism of action
AK Larsen, CM Galmarini, M D'Incalci - Cancer chemotherapy and …, 2016 - Springer
Trabectedin (Yondelis ® , ET-743) is a marine-derived natural product that was initially isolated
from the marine ascidian Ecteinascidia turbinata and is currently prepared synthetically. …
from the marine ascidian Ecteinascidia turbinata and is currently prepared synthetically. …
Targeting triple negative breast cancer: is p53 the answer?
…, O Siclari, I Migliaccio, L Santarpia, M D'Incalci… - Cancer treatment …, 2013 - Elsevier
Triple negative breast cancers, which are defined by lack of expression of estrogen, progesterone,
or HER2 receptors, represent approximately 15% of all breast cancers, although they …
or HER2 receptors, represent approximately 15% of all breast cancers, although they …
[PDF][PDF] Role of macrophage targeting in the antitumor activity of trabectedin
…, CM Galmarini, A Anichini, A Mantovani, M D'Incalci… - Cancer cell, 2013 - cell.com
There is widespread interest in macrophages as a therapeutic target in cancer. Here, we
demonstrate that trabectedin, a recently approved chemotherapeutic agent, induces rapid …
demonstrate that trabectedin, a recently approved chemotherapeutic agent, induces rapid …
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
…, E Tamborini, JC Tercero, J Jimeno, M D'Incalci… - The lancet …, 2007 - thelancet.com
Background Previous studies have suggested that trabectedin (ecteinascidin-743) could have
antitumour activity in soft-tissue sarcoma. We aimed to study the usefulness of trabectedin …
antitumour activity in soft-tissue sarcoma. We aimed to study the usefulness of trabectedin …
Role of α1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571
…, G Corneo, F Formelli, M D'Incalci - Journal of the …, 2000 - academic.oup.com
Background: Chronic myeloid leukemia is caused by a chromosomal translocation that
results in an oncogenic fusion protein, Bcr-Abl. Bcr-Abl is a tyrosine kinase whose activity is …
results in an oncogenic fusion protein, Bcr-Abl. Bcr-Abl is a tyrosine kinase whose activity is …
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production
…, A Garbi, A Lissoni, F de Braud, J Jimeno, M D'Incalci - Cancer research, 2005 - AACR
Yondelis (Trabectedin) is a novel antitumor agent of marine origin extracted from the tunicate
Ecteinascidia turbinata. This original compound is active against several human tumors …
Ecteinascidia turbinata. This original compound is active against several human tumors …
Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat
…, P Marmiroli, M Bossi, N Oggioni, M D'Incalci… - Experimental …, 2007 - Elsevier
Bortezomib is a new proteasome inhibitor with a high antitumor activity, but also with a
potentially severe peripheral neurotoxicity. To establish a preclinical model and to characterize …
potentially severe peripheral neurotoxicity. To establish a preclinical model and to characterize …